Literature DB >> 21253759

Corneal perforation due to limbal involvement in Sézary syndrome.

Iain Livingstone1, Saraswathi Ramamurthi, Suzannah Drummond, Ewan Kemp, Fiona Roberts.   

Abstract

BACKGROUND: The majority of lymphomas involving the eye and ocular adnexa are B-cell lymphomas. Ocular involvement by T-cell lymphoma is rare. We report a case of corneal perforation due to direct involvement of the corneal limbus by lymphoma in a patient with Sézary syndrome.
METHODS: A 58-year-old male with cutaneous T-cell lymphoma presented with painful, left-sided corneal ulceration, a dense infiltrate, severe epitheliopathy, hypopyon and a diffuse confluent dermatitis involving the lids. He had a history of Sézary syndrome. Despite maximal treatment, this severe ulcerative keratitis progressed to central corneal perforation. The eye was subsequently enucleated and submitted for histopathological examination.
RESULTS: Histopathological examination confirmed corneal ulceration with perforation. There was an infiltrate of large atypical cells at the limbus, with tropism for the overlying epithelium. Immunohistochemical staining of these cells was positive for CD2, CD3, CD5, CD4 and CD7. Staining for CD8, CD30 and CD56 was negative. The appearances were those of an epitheliotrophic T-cell lymphoma, and were considered to represent spread from the patient's underlying Sézary syndrome. The patient died 2 months later from bronchopneumonia.
CONCLUSIONS: Ocular involvement by cutaneous T-cell lymphoma usually occurs in advanced disease, and carries a poor prognosis. This patient was immunocompromised due to advanced malignancy, and there was a high suspicion of infection as the primary cause of corneal ulceration. This case highlights that it is important to consider direct tumour infiltration as an initiating or contributing factor for corneal ulceration in such patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253759     DOI: 10.1007/s00417-010-1611-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  11 in total

1.  T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.

Authors:  S E Coupland; H D Foss; C Assaf; C Auw-Haedrich; G Anastassiou; I Anagnostopoulos; M Hummel; J W Karesh; W R Lee; H Stein
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

2.  Monitoring of the disease progress in Sezary syndrome by cd7- cells using flow cytometry.

Authors:  C Collenberg; P von den Driesch; M Gramatzki; M Fartasch; M S Gruschwitz
Journal:  Br J Dermatol       Date:  1996-05       Impact factor: 9.302

3.  Bilateral orbital infiltration as the initial sign of a peripheral T-cell lymphoma presenting in a leukemic phase.

Authors:  M D Sherman; J T Van Dalen; K Conrad
Journal:  Ann Ophthalmol       Date:  1990-03

4.  Mycosis fungoides involving the caruncle.

Authors:  A H Fradkin; R S Ruiz; J A Sloane
Journal:  Am J Ophthalmol       Date:  1969-10       Impact factor: 5.258

5.  Mycosis fungoides of upper lid.

Authors:  A R Deutsch; J K Duckworth
Journal:  Am J Ophthalmol       Date:  1968-06       Impact factor: 5.258

6.  Mycosis fungoides metastatic to the orbit.

Authors:  J L Zucker; M F Doyle
Journal:  Arch Ophthalmol       Date:  1991-05

7.  Mycosis fungoides: subcutaneous and visceral tumors, orbital involvement, and ophthalmoplegia.

Authors:  E G Whitbeck; A S Spiers; M Hussain
Journal:  J Clin Oncol       Date:  1983-04       Impact factor: 44.544

8.  Ocular findings in cutaneous T-cell lymphoma.

Authors:  M L Leib; H Lester; R E Braunstein; R L Edelson
Journal:  Ann Ophthalmol       Date:  1991-05

9.  Cutaneous T-cell lymphoma presenting as a rapidly enlarging ocular adnexal tumor.

Authors:  B Meekins; A D Proia; G K Klintworth
Journal:  Ophthalmology       Date:  1985-09       Impact factor: 12.079

10.  Ocular findings in mycosis fungoides.

Authors:  S Stenson; D L Ramsay
Journal:  Arch Ophthalmol       Date:  1981-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.